vs

Side-by-side financial comparison of GLADSTONE COMMERCIAL CORP (GOOD) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

GLADSTONE COMMERCIAL CORP is the larger business by last-quarter revenue ($43.5M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.). GLADSTONE COMMERCIAL CORP runs the higher net margin — 12.4% vs -304.2%, a 316.6% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 16.3%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 10.3%).

Gladstone Commercial Corp is a publicly traded US real estate investment trust focused on acquiring, owning, and operating diversified industrial and commercial properties. It offers long-term net lease agreements to tenants across manufacturing, logistics, healthcare and professional services sectors, mainly serving small to mid-sized business clients.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

GOOD vs RXRX — Head-to-Head

Bigger by revenue
GOOD
GOOD
1.2× larger
GOOD
$43.5M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+665.5% gap
RXRX
681.7%
16.3%
GOOD
Higher net margin
GOOD
GOOD
316.6% more per $
GOOD
12.4%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
10.3%
GOOD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GOOD
GOOD
RXRX
RXRX
Revenue
$43.5M
$35.5M
Net Profit
$5.4M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
12.4%
-304.2%
Revenue YoY
16.3%
681.7%
Net Profit YoY
-25.1%
39.6%
EPS (diluted)
$0.05
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GOOD
GOOD
RXRX
RXRX
Q4 25
$43.5M
$35.5M
Q3 25
$40.8M
$5.2M
Q2 25
$39.5M
$19.2M
Q1 25
$37.5M
$14.7M
Q4 24
$37.4M
$4.5M
Q3 24
$39.2M
$26.1M
Q2 24
$37.1M
$14.4M
Q1 24
$35.7M
$13.8M
Net Profit
GOOD
GOOD
RXRX
RXRX
Q4 25
$5.4M
$-108.1M
Q3 25
$4.1M
$-162.3M
Q2 25
$4.6M
$-171.9M
Q1 25
$5.1M
$-202.5M
Q4 24
$7.2M
$-178.9M
Q3 24
$11.7M
$-95.8M
Q2 24
$1.6M
$-97.5M
Q1 24
$3.5M
$-91.4M
Gross Margin
GOOD
GOOD
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
GOOD
GOOD
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
GOOD
GOOD
RXRX
RXRX
Q4 25
12.4%
-304.2%
Q3 25
10.1%
-3135.3%
Q2 25
11.7%
-894.2%
Q1 25
13.7%
-1373.3%
Q4 24
19.2%
-3935.5%
Q3 24
29.8%
-367.5%
Q2 24
4.3%
-676.6%
Q1 24
9.9%
-662.4%
EPS (diluted)
GOOD
GOOD
RXRX
RXRX
Q4 25
$0.05
$-0.17
Q3 25
$0.02
$-0.36
Q2 25
$0.03
$-0.41
Q1 25
$0.04
$-0.50
Q4 24
$0.10
$-0.56
Q3 24
$0.20
$-0.34
Q2 24
$-0.04
$-0.40
Q1 24
$0.01
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GOOD
GOOD
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$10.8M
$743.3M
Total DebtLower is stronger
$843.5M
$9.6M
Stockholders' EquityBook value
$171.8M
$1.1B
Total Assets
$1.2B
$1.5B
Debt / EquityLower = less leverage
4.91×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GOOD
GOOD
RXRX
RXRX
Q4 25
$10.8M
$743.3M
Q3 25
$18.4M
$659.8M
Q2 25
$11.7M
$525.1M
Q1 25
$10.4M
$500.5M
Q4 24
$11.0M
$594.4M
Q3 24
$10.5M
$427.6M
Q2 24
$10.4M
$474.3M
Q1 24
$10.5M
$296.3M
Total Debt
GOOD
GOOD
RXRX
RXRX
Q4 25
$843.5M
$9.6M
Q3 25
$843.3M
$11.9M
Q2 25
$794.4M
$14.2M
Q1 25
$740.7M
$16.4M
Q4 24
$693.4M
$19.0M
Q3 24
$692.6M
$20.5M
Q2 24
$722.5M
$22.9M
Q1 24
$719.4M
Stockholders' Equity
GOOD
GOOD
RXRX
RXRX
Q4 25
$171.8M
$1.1B
Q3 25
$184.8M
$1.0B
Q2 25
$177.2M
$919.1M
Q1 25
$183.2M
$933.9M
Q4 24
$171.2M
$1.0B
Q3 24
$168.9M
$524.6M
Q2 24
$145.7M
$584.4M
Q1 24
$147.3M
$401.2M
Total Assets
GOOD
GOOD
RXRX
RXRX
Q4 25
$1.2B
$1.5B
Q3 25
$1.3B
$1.4B
Q2 25
$1.2B
$1.3B
Q1 25
$1.2B
$1.3B
Q4 24
$1.1B
$1.4B
Q3 24
$1.1B
$726.5M
Q2 24
$1.1B
$775.9M
Q1 24
$1.1B
$557.8M
Debt / Equity
GOOD
GOOD
RXRX
RXRX
Q4 25
4.91×
0.01×
Q3 25
4.56×
0.01×
Q2 25
4.48×
0.02×
Q1 25
4.04×
0.02×
Q4 24
4.05×
0.02×
Q3 24
4.10×
0.04×
Q2 24
4.96×
0.04×
Q1 24
4.88×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GOOD
GOOD
RXRX
RXRX
Operating Cash FlowLast quarter
$88.2M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
16.38×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GOOD
GOOD
RXRX
RXRX
Q4 25
$88.2M
$-46.1M
Q3 25
$18.9M
$-117.4M
Q2 25
$35.8M
$-76.4M
Q1 25
$17.7M
$-132.0M
Q4 24
$57.0M
$-115.4M
Q3 24
$5.5M
$-59.2M
Q2 24
$13.6M
$-82.2M
Q1 24
$15.0M
$-102.3M
Free Cash Flow
GOOD
GOOD
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
GOOD
GOOD
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
GOOD
GOOD
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
GOOD
GOOD
RXRX
RXRX
Q4 25
16.38×
Q3 25
4.57×
Q2 25
7.74×
Q1 25
3.44×
Q4 24
7.93×
Q3 24
0.47×
Q2 24
8.44×
Q1 24
4.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons